Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance in plaque psoriasis (LIMMITLESS)
NCT03047395Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2017
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of risankizumab in plaque psoriasis, sponsored by AbbVie Inc.. Started Feb 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03047395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03047395.